Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1

The structure-based design of small-molecule inhibitors targeting protein–protein interactions (PPIs) remains a huge challenge as the drug must bind typically wide and shallow protein sites. A PPI target of high interest for hematological cancer therapy is myeloid cell leukemia 1 (Mcl-1), a prosurvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hargreaves, David, Carbajo, Rodrigo J., Bodnarchuk, Michael S., Embrey, Kevin, Rawlins, Philip B., Packer, Martin, Degorce, Sébastien L., Hird, Alexander W., Johannes, Jeffrey W., Chiarparin, Elisabetta, Schade, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Physical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214187/
https://www.ncbi.nlm.nih.gov/pubmed/37186857
http://dx.doi.org/10.1073/pnas.2221967120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214187/
https://www.ncbi.nlm.nih.gov/pubmed/37186857
http://dx.doi.org/10.1073/pnas.2221967120

Ejemplares similares